Skip to content
Inciteful Med

Treatment Strategy & Symptom Management for DM1

Last updated:

While there is no cure for Myotonic Dystrophy Type 1 (DM1), proactive multidisciplinary care can significantly improve quality of life. Treatment focuses on managing specific symptoms using medications for muscle stiffness, strict cardiac monitoring, and nighttime breathing support.

Key Takeaways

  • • DM1 requires a multidisciplinary care team, including a neurologist, cardiologist, and pulmonologist.
  • • Medications like mexiletine can treat muscle stiffness but require strict cardiac clearance before use.
  • • Regular heart monitoring is essential, as DM1 frequently causes dangerous conduction delays and arrhythmias.
  • • Breathing weakness and sleep apnea are major complications that are highly manageable with nocturnal breathing support like a BiPAP machine.
  • • New disease-modifying therapies targeting the toxic RNA that causes DM1 are currently being tested in clinical trials.

While there is currently no cure or disease-modifying therapy for Myotonic Dystrophy Type 1 (DM1), proactive and coordinated care can significantly improve your quality of life and long-term health [1][2]. Because DM1 affects so many different systems, the standard of care is a multidisciplinary approach, where a team of specialists works together to manage your specific symptoms [3][4].

Building Your Care Team

A high-quality care team for DM1 typically includes several key specialists:

  • Neurologist: Often the lead doctor who monitors muscle strength and coordination [1].
  • Cardiologist: Focuses on the heart’s rhythm and conduction system [5].
  • Pulmonologist (Lung Specialist): Monitors breathing strength and sleep-disordered breathing [6].
  • Physical and Occupational Therapists: Help maintain mobility and adapt daily tasks [7].

Symptom Management Guide

Medical research has identified effective ways to manage the most common challenges of DM1:

Neuromuscular Symptoms

  • Myotonia (Muscle Stiffness): Mexiletine is a medication frequently used to help muscles relax more easily [8][9]. Crucial Safety Warning: Mexiletine is an antiarrhythmic medication that can affect how the heart beats. Because DM1 so frequently causes heart conduction delays, you must have a baseline ECG and strict clearance from a cardiologist before starting this or similar medications [10][11].
  • Weakness: While no pill restores muscle, endurance exercise and physical therapy can help maintain your current strength and function [12][13]. Note: Any new exercise routine must also be cleared by your cardiologist.

Cardiac Health

Because the heart’s electrical system can be affected, regular monitoring is essential [5][14].

  • Conduction Issues: If electrical signals in the heart slow down, a pacemaker may be needed to keep the heart beating at the right speed [15][16].
  • Arrhythmias: For more serious irregular heartbeats, an Implantable Cardioverter-Defibrillator (ICD) may be recommended to prevent sudden cardiac events [5][17].

Respiratory and Sleep Issues

Breathing weakness is a major driver of health complications, but it is highly manageable if caught early [6][18].

  • Sleep Apnea/Nocturnal Hypoventilation: Non-Invasive Ventilation (NIV), such as a BiPAP machine, is used at night to support your breathing while you sleep [19][20].
  • Excessive Daytime Sleepiness: Medications like modafinil may be prescribed to help you stay alert during the day [8][21].

Other Systemic Issues

  • Cataracts: These are usually treated with standard surgical removal [22].
  • GI Issues: Diet changes and certain medications can help manage constipation or swallowing difficulties [23].
  • Fatigue and Apathy: Cognitive Behavioral Therapy (CBT) has shown success in helping patients manage fatigue and stay engaged in social activities [24].

The Future of Treatment

The research landscape is changing rapidly. Scientists are currently testing several “disease-modifying” therapies in clinical trials, including Antisense Oligonucleotides (ASOs) and other molecules designed to target the toxic RNA that causes DM1 [25][26]. While these are not yet available for general use, they represent a significant step toward a future where we can treat the cause of the disease, not just the symptoms [27][28].

Frequently Asked Questions

What doctors should be on my DM1 care team?
Because DM1 affects many different body systems, patients need a coordinated, multidisciplinary approach to care. A standard care team typically includes a neurologist, cardiologist, pulmonologist, and physical and occupational therapists.
What is the best treatment for muscle stiffness in DM1?
Mexiletine is a medication frequently used to help muscles relax and reduce myotonia (stiffness). However, because it can affect heart rhythms, you must get clearance from a cardiologist and have a baseline ECG before starting it.
How does myotonic dystrophy affect the heart?
Myotonic Dystrophy Type 1 can slow down the heart's electrical signals and cause irregular heartbeats. Regular monitoring by a cardiologist is essential, and some patients may require a pacemaker or implantable cardioverter-defibrillator (ICD) to keep the heart beating safely.
How is excessive daytime sleepiness treated in DM1?
Daytime sleepiness can be managed with wakefulness-promoting medications like modafinil. It is also critical to treat any underlying nocturnal breathing issues, such as sleep apnea, which are commonly managed using a BiPAP machine at night.
Is there a cure for Myotonic Dystrophy Type 1?
There is currently no cure or approved disease-modifying therapy for DM1, meaning treatment focuses on managing symptoms. However, researchers are actively testing new therapies in clinical trials, such as targeted RNA treatments, that aim to treat the root cause of the disease.

Questions for Your Doctor

  • • Can you help me coordinate a multidisciplinary care team, and who will be the main 'point person' for my care?
  • • Is mexiletine a safe option for my myotonia, and do we need to do extra heart monitoring if I start it?
  • • When should I have my first sleep study and pulmonary function test to check for breathing issues?
  • • What are the specific 'red flag' symptoms that should trigger an immediate call to the cardiologist?
  • • Are there any clinical trials for new DM1 treatments that I might be eligible for?

Questions for You

  • • Which symptoms—like muscle stiffness, fatigue, or digestion—are having the biggest impact on your daily life right now?
  • • Do you feel safe driving or working, or does daytime sleepiness make those activities difficult?
  • • How much support do you have at home to help manage appointments and treatments?
  • • What are your top priorities for your health: Is it maintaining strength, improving sleep, or managing pain?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Myotonic dystrophy type 2: the 2020 update.

    Meola G

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.

    PMID: 33458578
  2. 2

    Myotonic Muscular Dystrophies.

    Johnson NE

    Continuum (Minneapolis, Minn.) 2019; (25(6)):1682-1695 doi:10.1212/CON.0000000000000793.

    PMID: 31794466
  3. 3

    Clinical and genetic characteristics of childhood-onset myotonic dystrophy.

    Stokes M, Varughese N, Iannaccone S, Castro D

    Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.

    PMID: 31520483
  4. 4

    Consensus-based care recommendations for adults with myotonic dystrophy type 1.

    Ashizawa T, Gagnon C, Groh WJ, et al.

    Neurology. Clinical practice 2018; (8(6)):507-520 doi:10.1212/CPJ.0000000000000531.

    PMID: 30588381
  5. 5

    [Myotonic dystrophy type 1 - a rare cause of bradycardia in the young].

    Kataja Knight A, Tidehag L, Mattsson G, Magnusson P

    Lakartidningen 2020; (117()).

    PMID: 31961442
  6. 6

    Sudden Death Caused by Bilateral Diaphragmatic Eventration in Myotonic Dystrophy Type 1.

    Wu S, Prahlow JA

    The American journal of forensic medicine and pathology 2025; (46(4)):330-336 doi:10.1097/PAF.0000000000001073.

    PMID: 40928346
  7. 7

    Daily activity performance in congenital and childhood forms of myotonic dystrophy type 1: a population-based study.

    Eriksson BM, Ekström AB, Peny-Dahlstrand M

    Developmental medicine and child neurology 2020; (62(6)):723-728 doi:10.1111/dmcn.14395.

    PMID: 31701525
  8. 8

    Excessive daytime sleepiness in myotonic dystrophy: a narrative review.

    Hoxhaj D, Pascazio A, Maestri M, et al.

    Frontiers in neurology 2024; (15()):1389949 doi:10.3389/fneur.2024.1389949.

    PMID: 39011358
  9. 9

    Myotonic dystrophy type 1 drug development: A pipeline toward the market.

    Pascual-Gilabert M, López-Castel A, Artero R

    Drug discovery today 2021; (26(7)):1765-1772 doi:10.1016/j.drudis.2021.03.024.

    PMID: 33798646
  10. 10

    Idiopathic ventricular fibrillation and the V1764fsX1786 frameshift mutation of the SCN5A gene in a myotonic dystrophy type 1 patient.

    Shimoyama T, Hayashi H, Suzuki F, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020; (74()):242-244 doi:10.1016/j.jocn.2020.02.007.

    PMID: 32063450
  11. 11

    Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.

    Locci S, Cardani R, Brunori P, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):5365-5368 doi:10.1007/s10072-021-05538-y.

    PMID: 34386887
  12. 12

    Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

    Sharp L, Cox DC, Cooper TA

    Muscle & nerve 2019; (60(6)):779-789 doi:10.1002/mus.26709.

    PMID: 31509256
  13. 13

    Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

    Manta A, Stouth DW, Xhuti D, et al.

    The Journal of physiology 2019; (597(5)):1361-1381 doi:10.1113/JP277123.

    PMID: 30628727
  14. 14

    Myotonic Dystrophy.

    Hamel JI

    Continuum (Minneapolis, Minn.) 2022; (28(6)):1715-1734 doi:10.1212/CON.0000000000001184.

    PMID: 36537977
  15. 15

    Myocardial fibrosis by late gadolinium enhancement cardiovascular magnetic resonance in myotonic muscular dystrophy type 1: highly prevalent but not associated with surface conduction abnormality.

    Cardona A, Arnold WD, Kissel JT, et al.

    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2019; (21(1)):26 doi:10.1186/s12968-019-0535-6.

    PMID: 31046780
  16. 16

    Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.

    Wahbi K, Babuty D, Probst V, et al.

    European heart journal 2017; (38(10)):751-758 doi:10.1093/eurheartj/ehw569.

    PMID: 27941019
  17. 17

    Prevalence of Left Ventricular Systolic Dysfunction in Myotonic Dystrophy Type 1: A Systematic Review.

    Russo V, Sperlongano S, Gallinoro E, et al.

    Journal of cardiac failure 2020; (26(10)):849-856 doi:10.1016/j.cardfail.2019.07.548.

    PMID: 31415861
  18. 18

    Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.

    Gallinoro E, Papa AA, Rago A, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2018; (37(3)):227-231.

    PMID: 30838353
  19. 19

    New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation.

    Seijger C, Raaphorst J, Vonk J, et al.

    Respiration; international review of thoracic diseases 2021; (100(2)):154-163 doi:10.1159/000511962.

    PMID: 33461194
  20. 20

    Treatment of sleep central apnea with non-invasive mechanical ventilation with 2 levels of positive pressure (bilevel) in a patient with myotonic dystrophy type 1.

    Akamine RT, Grossklauss LF, Moreira GA, et al.

    Sleep science (Sao Paulo, Brazil) 2014; (7(2)):117-21 doi:10.1016/j.slsci.2014.09.002.

    PMID: 26483914
  21. 21

    Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.

    West SD, Lochmüller H, Hughes J, et al.

    Journal of neuromuscular diseases 2016; (3(4)):529-537 doi:10.3233/JND-160191.

    PMID: 27911338
  22. 22

    [Eye disease with myotonic dystrophy type 1].

    Boonstra NE, Varhaug KN

    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2023; (143(13)) doi:10.4045/tidsskr.22.0608.

    PMID: 37753768
  23. 23

    High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

    Hilbert JE, Barohn RJ, Clemens PR, et al.

    Neurology 2017; (89(13)):1348-1354 doi:10.1212/WNL.0000000000004420.

    PMID: 28855409
  24. 24

    Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.

    Okkersen K, Jimenez-Moreno C, Wenninger S, et al.

    The Lancet. Neurology 2018; (17(8)):671-680 doi:10.1016/S1474-4422(18)30203-5.

    PMID: 29934199
  25. 25

    Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1.

    Bérenger-Currias N, Martinat C, Baghdoyan S

    Cells 2023; (12(4)) doi:10.3390/cells12040571.

    PMID: 36831237
  26. 26

    Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives.

    Rahm L, Hale MA, Raaijmakers RHL, et al.

    Nature reviews. Neurology 2025; (21(11)):623-641 doi:10.1038/s41582-025-01139-x.

    PMID: 40983775
  27. 27

    From molecular convergence to clinical divergence: Comparative pathogenic mechanisms and therapeutic trajectories in C9orf72-ALS/FTD and myotonic dystrophy.

    Alberti C, Parente V, Corti S, Sansone VA

    Neurobiology of disease 2025; (217()):107192 doi:10.1016/j.nbd.2025.107192.

    PMID: 41260310
  28. 28

    The myotonic dystrophy type 1 drug development pipeline: 2022 edition.

    Pascual-Gilabert M, Artero R, López-Castel A

    Drug discovery today 2023; (28(3)):103489 doi:10.1016/j.drudis.2023.103489.

    PMID: 36634841

This page provides educational information about managing Myotonic Dystrophy Type 1 (DM1). Always consult your neurologist and multidisciplinary care team before starting new medications, treatments, or exercise routines.

Stay up to date

Get notified when new research about Steinert myotonic dystrophy is published.

No spam. Unsubscribe anytime.